| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.443 | 7.805 | 7.546 | 8.699 | 7.700 | 57.421 | 52.640 | 51.811 | 52.899 | 71.856 |
| Total Income - EUR | 2.030 | 7.325 | 7.546 | 8.699 | 7.700 | 57.421 | 56.684 | 51.811 | 52.899 | 73.876 |
| Total Expenses - EUR | 1.861 | 10.834 | 6.708 | 8.788 | 6.780 | 54.423 | 65.446 | 46.568 | 51.207 | 87.633 |
| Gross Profit/Loss - EUR | 169 | -3.509 | 838 | -89 | 920 | 2.998 | -8.762 | 5.244 | 1.692 | -13.757 |
| Net Profit/Loss - EUR | 125 | -3.745 | 612 | -350 | 688 | 2.457 | -9.632 | 4.499 | 1.168 | -13.757 |
| Employees | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Iris Enzymes Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 404 | 442 | 434 | 0 | 0 | 12.081 | 0 | 0 | 19.721 | 16.801 |
| Current Assets | 1.459 | 5.194 | 6.947 | 4.878 | 6.972 | 33.857 | 17.196 | 26.395 | 24.251 | 46.572 |
| Inventories | 816 | 880 | 2.122 | 1.528 | 1.259 | 1.654 | 750 | 1.426 | 1.611 | 11.036 |
| Receivables | 211 | 3.526 | 4.720 | 3.048 | 4.732 | 22.353 | 14.924 | 23.035 | 21.658 | 34.292 |
| Cash | 432 | 789 | 105 | 302 | 981 | 9.849 | 1.522 | 1.935 | 982 | 1.245 |
| Shareholders Funds | 170 | -3.577 | -2.905 | -3.201 | -2.451 | 53 | -9.580 | -5.111 | -3.928 | -17.663 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.693 | 9.213 | 10.286 | 8.079 | 9.422 | 45.908 | 26.776 | 31.506 | 49.907 | 81.036 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "1089 - 1089" | |||||||||
| CAEN Financial Year |
1089
|
|||||||||
Comments - Iris Enzymes Srl